Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.

CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple ...

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses ...

Cancer remission can be partial, complete, or spontaneous. For cancer to be in remission, a decrease in cancer signs for at least a month must be observed. Cancers in remission, however, may come ...

The draw, held earlier this week, required candidates to have a minimum Comprehensive Ranking System (CRS) score of 727. This marks the third Express Entry draw of December. The first, on December 2, ...

This is also called stage 4c bowel cancer. Surgery combined with chemotherapy is also called cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). It involves: the ...

Bone cancer is when cells in your bones grow out of control. Usually, when you have bone cancer, it comes from another cancer that has spread to your bones or metastatic bone cancer. But ...

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...